ELSEVIER

Clinica Chimica Acta 268 (1997) 133–134

# Author index

## Volume 268 (1997)

Alvarez, V., see Ricós, C. **268**, 73

Bellometti, S., Cecchettin, M., Galzigna, L., Mud pack therapy in osteoarthrosis. Changes in serum levels of chondrocyte markers **268**, 101
Bruunshuus, I., see Cornelis, R. **268**, S75
Bruunshuus, I., see Olesen, H. **268**, S5
Büttner, C., see Schmidt, H.H.-J. **268**, 41

Campbell, J.M., see Reglinski, J. **268**, 85
Cecchettin, M., see Bellometti, S. **268**, 101
Cornelis, R., Fuentes-Arderiu, X., Bruunshuus, I., Templeton, D., International Union of Pure and Applied Chemistry Clinical Chemistry Division, Commission on Toxicology (C-TOX), Commission on Nomenclature, Properties and Units (C-NPU) and International Federation of Clinical Chemistry, Scientific Division Committee on Nomenclature, Properties and Units (C-NPU). Properties and Units in the Clinical Laboratory Sciences. IX. Properties and Units in Trace Elements (IUPAC-IFCC Technical report 1997) **268**, S75
Cowan, D., see Olesen, H. **268**, S5
Cynober, L., see Minet, R. **268**, 121

Den Tandt, W.R., Scharpé, S., Plasma methylumbelliferyl-tetra-N-acetyl-chitotetraoside hydrolase: further study of its characteristics as a chitinase and comparison with its activity on Remazol Brilliant Violet carboxymethyl chitin **268**, 107
Dowling, R.H., see Thomas, L.A. **268**, 61

French, G.L., see Thomas, L.A. **268**, 61
Fuentes-Arderiu, X., see Cornelis, R. **268**, S75

Galzigna, L., see Bellometti, S. **268**, 101
Genschel, J., see Schmidt, H.H.-J. **268**, 41

Haas, R.E., see Schmidt, H.H.-J. **268**, 41
Hernández, A., see Ricós, C. **268**, 73
Hill, G., see Olesen, H. **268**, S5
Holmskov, U., see Jensen, C.H. **268**, 1

Inal, M., Sunal, E., Kanbak, G., Zeytinoğlu, S., Effects of postmenopausal hormone replacement and α-tocopherol on the lipid profiles and antioxidant status **268**, 21

Jensen, C.H., Krogh, T.N., Støving, R.K., Holmskov, U., Teisner, B., Fetal antigen 1 (FA1), a circulating member of the epidermal growth factor (EGF) superfamily: ELISA development, physiology and metabolism in relation to renal function **268**, 1
Jiménez, C.V., see Ricós, C. **268**, 73
Juvany, R., see Ricós, C. **268**, 73

Kanbak, G., see Inal, M. **268**, 21
King, A., see Thomas, L.A. **268**, 61
Klempel, K., see Olesen, H. **268**, S5
Krogh, T.N., see Jensen, C.H. **268**, 1

Latimer, S., see Reglinski, J. **268**, 85

Manns, M.P., see Schmidt, H.H.-J. **268**, 41
Marcollet, M., see Minet, R. **268**, 121
Maresch, L., see Vrecko, K. **268**, 31
Meynial-Denis, D., see Minet, R. **268**, 121
Minchinela, J., see Ricós, C. **268**, 73
Minet, R., Villie, F., Marcollet, M., Meynial-Denis, D., Cynober, L., Measurement of glutamine

0009-8981/97/$17.00 Elsevier Science B.V. All rights reserved
*PII* S0009-8981(97)00205-2

synthetase activity in rat muscle by a colorimetric assay **268**, 121
Mischak, I., see Vrecko, K. **268**, 31
Murphy, G.M., see Thomas, L.A. **268**, 61

Olesen, H., Cowan, D., Bruunshuus, I., Klempel, K., Hill, G., International Federation of Clinical Chemistry and International Union of Pure and Applied Chemistry. Properties and Units in the Clinical Laboratory Sciences. VI. Properties and Units in IOC Prohibited Drugs (IFCC-IUPAC Recommendations 1997) **268**, S5

Paterson, D.E., see Reglinski, J. **268**, 85
Perich, C., see Ricós, C. **268**, 73
Porter, D., see Reglinski, J. **268**, 85

Reglinski, J., Paterson, D.E., Latimer, S., Campbell, J.M., Wilson, R., Porter, D., Sturrock, R.D., Smith, W.E., Myocrisin-mediated oxidative stress **268**, 85
Reibnegger, G., see Vrecko, K. **268**, 31
Remaley, A., see Schmidt, H.H.-J. **268**, 41
Ricós, C., Juvany, R., Jiménez, C.V., Perich, C., Minchinela, J., Hernández, A., Simón, M., Alvarez, V., Procedure for studying commutability validated by biological variation **268**, 73

Scharpé, S., see Den Tandt, W.R. **268**, 107
Schmidt, H.H.-J., Haas, R.E., Remaley, A., Genschel, J., Strassburg, C.P., Büttner, C., Manns, M.P., *In vivo* kinetics as a sensitive method for testing physiologically intact human recombinant apolipoprotein A-I: comparison of three different expression systems **268**, 41
Simón, M., see Ricós, C. **268**, 73
Smith, W.E., see Reglinski, J. **268**, 85
Staedtler, P., see Vrecko, K. **268**, 31
Støving, R.K., see Jensen, C.H. **268**, 1
Strassburg, C.P., see Schmidt, H.H.-J. **268**, 41
Sturrock, R.D., see Reglinski, J. **268**, 85
Sunal, E., see Inal, M. **268**, 21

Teisner, B., see Jensen, C.H. **268**, 1
Templeton, D., see Cornelis, R. **268**, S75
Thomas, L.A., King, A., French, G.L., Murphy, G.M., Dowling, R.H., Cholylglycine hydrolase and 7α-dehydroxylase optimum assay conditions in vitro and caecal enzyme activities ex vivo **268**, 61

Villie, F., see Minet, R. **268**, 121
Vrecko, K., Staedtler, P., Mischak, I., Maresch, L., Reibnegger, G., Periodontitis and concentrations of the cellular immune activation marker neopterin in saliva and urine **268**, 31

Wilson, R., see Reglinski, J. **268**, 85

Zeytinoğlu, S., see Inal, M. **268**, 21

ELSEVIER

Clinica Chimica Acta 268 (1997) 135–137

# Subject index

## Volume 268 (1997)

**Amniotic fluid**; Kidney function; Circadian rhythm; ELISA; Reference values; Metabolic clearance rate; Fetal antigen 1; Preadipocyte factor 1; Epidermal growth factor-like **268**, 1

**Baculovirus**; CHO cells; *E. coli*; Recombinant apoA-I; *In vivo* kinetics **268**, 41

**Cartilage**; Mud-pack therapy; Osteoarthrosis; Cytokines **268**, 101

**Cellular immunity**; Periodontitis; CPITN; Immune activation; Neopterin **268**, 31

**Chitinase**; Methylumbelliferyl-tetra-N-acetylchitotetraoside hydrolase; Lysozyme; Remazol Brilliant Violet carboxymethyl (RBV) chitin hydrolase **268**, 107

**CHO cells**; *E. coli*; Baculovirus; Recombinant apoA-I; *In vivo* kinetics **268**, 41

**Cholylglycine hydrolase**; 7α-Dehydroxylase; Deoxycholic acid; Gallstones **268**, 61

**Circadian rhythm**; Kidney function; ELISA; Amniotic fluid; Reference values; Metabolic clearance rate; Fetal antigen 1; Preadipocyte factor 1; Epidermal growth factor-like **268**, 1

**Colorimetry**; Glutamine synthetase; Glutamyl transferase; Muscle **268**, 121

**Commutability**; Quality assurance; Transferability **268**, 73

**CPITN**; Periodontitis; Immune activation; Cellular immunity; Neopterin **268**, 31

**Cytokines**; Mud-pack therapy; Osteoarthrosis; Cartilage **268**, 101

**7α-Dehydroxylase**; Cholylglycine hydrolase; Deoxycholic acid; Gallstones **268**, 61

**Deoxycholic acid**; Cholylglycine hydrolase; 7α-Dehydroxylase; Gallstones **268**, 61

***E. coli***; CHO cells; Baculovirus; Recombinant apoA-I; *In vivo* kinetics **268**, 41

**ELISA**; Kidney function; Circadian rhythm; Amniotic fluid; Reference values; Metabolic clearance rate; Fetal antigen 1; Preadipocyte factor 1; Epidermal growth factor-like **268**, 1

**Epidermal growth factor-like**; Kidney function; Circadian rhythm; ELISA; Amniotic fluid; Reference values; Metabolic clearance rate; Fetal antigen 1; Preadipocyte factor 1 **268**, 1

**Fetal antigen 1**; Kidney function; Circadian rhythm; ELISA; Amniotic fluid; Reference values; Metabolic clearance rate; Preadipocyte factor 1; Epidermal growth factor-like **268**, 1

**Gallstones**; Cholylglycine hydrolase; 7α-Dehydroxylase; Deoxycholic acid **268**, 61

**Glutamine synthetase**; Glutamyl transferase; Muscle; Colorimetry **268**, 121

0009-8981/97/$17.00 Elsevier Science B.V. All rights reserved
*PII* S0009-8981(97)00206-4

**Glutamyl transferase**; Glutamine synthetase; Muscle; Colorimetry **268**, 121

**Glutathione peroxidase**; Rheumatoid arthritis; Gold; Hydrogen peroxide; Monocytes **268**, 85

**Gold**; Rheumatoid arthritis; Hydrogen peroxide; Glutathione peroxidase; Monocytes **268**, 85

**Hydrogen peroxide**; Rheumatoid arthritis; Gold; Glutathione peroxidase; Monocytes **268**, 85

**Immune activation**; Periodontitis; CPITN; Cellular immunity; Neopterin **268**, 31

***In vivo* kinetics**; CHO cells; *E. coli*; Baculovirus; Recombinant apoA-I **268**, 41

**Kidney function**; Circadian rhythm; ELISA; Amniotic fluid; Reference values; Metabolic clearance rate; Fetal antigen 1; Preadipocyte factor 1; Epidermal growth factor-like **268**, 1

**Lipoprotein**; Postmenopausal; Transdermal oestradiol; Progesterone; α-Tocopherol; Malondialdehyde; Reduced glutathione; Superoxide dismutase **268**, 21

**Lysozyme**; Methylumbelliferyl-tetra-N-acetylchitotetraoside hydrolase; Chitinase; Remazol Brilliant Violet carboxymethyl (RBV) chitin hydrolase **268**, 107

**Malondialdehyde**; Postmenopausal; Transdermal oestradiol; Progesterone; α-Tocopherol; Reduced glutathione; Superoxide dismutase; Lipoprotein **268**, 21

**Metabolic clearance rate**; Kidney function; Circadian rhythm; ELISA; Amniotic fluid; Reference values; Fetal antigen 1; Preadipocyte factor 1; Epidermal growth factor-like **268**, 1

**Methylumbelliferyl-tetra-N-acetylchitotetraoside hydrolase**; Chitinase; Lysozyme; Remazol Brilliant Violet carboxymethyl (RBV) chitin hydrolase **268**, 107

**Monocytes**; Rheumatoid arthritis; Gold; Hydrogen peroxide; Glutathione peroxidase **268**, 85

**Mud-pack therapy**; Osteoarthrosis; Cytokines; Cartilage **268**, 101

**Muscle**; Glutamine synthetase; Glutamyl transferase; Colorimetry **268**, 121

**Neopterin**; Periodontitis; CPITN; Immune activation; Cellular immunity **268**, 31

**Osteoarthrosis**; Mud-pack therapy; Cytokines; Cartilage **268**, 101

**Periodontitis**; CPITN; Immune activation; Cellular immunity; Neopterin **268**, 31

**Postmenopausal**; Transdermal oestradiol; Progesterone; α-Tocopherol; Malondialdehyde; Reduced glutathione; Superoxide dismutase; Lipoprotein **268**, 21

**Preadipocyte factor 1**; Kidney function; Circadian rhythm; ELISA; Amniotic fluid; Reference values; Metabolic clearance rate; Fetal antigen 1; Epidermal growth factor-like **268**, 1

**Progesterone**; Postmenopausal; Transdermal oestradiol; α-Tocopherol; Malondialdehyde; Reduced glutathione; Superoxide dismutase; Lipoprotein **268**, 21

**Quality assurance**; Commutability; Transferability **268**, 73

**Recombinant apoA-I**; CHO cells; *E. coli*; Baculovirus; *In vivo* kinetics **268**, 41

**Reduced glutathione**; Postmenopausal; Transdermal oestradiol; Progesterone; α-Tocopherol; Malondialdehyde; Superoxide dismutase; Lipoprotein **268**, 21

**Reference values**; Kidney function; Circadian rhythm; ELISA; Amniotic fluid; Metabolic clearance rate; Fetal antigen 1; Preadipocyte factor 1; Epidermal growth factor-like **268**, 1

**Remazol Brilliant Violet carboxymethyl (RBV) chitin hydrolase**; Methylumbelliferyl-tetra-N-acetylchitotetraoside hydrolase; Chitinase; Lysozyme **268**, 107

**Rheumatoid arthritis**; Gold; Hydrogen peroxide; Glutathione peroxidase; Monocytes **268**, 85

**Superoxide dismutase**; Postmenopausal; Transdermal oestradiol; Progesterone; α-Tocopherol;

Malondialdehyde; Reduced glutathione; Lipoprotein **268**, 21

**α-Tocopherol**; Postmenopausal; Transdermal oestradiol; Progesterone; Malondialdehyde; Reduced glutathione; Superoxide dismutase; Lipoprotein **268**, 21

**Transdermal oestradiol**; Postmenopausal; Progesterone; α-Tocopherol; Malondialdehyde; Reduced glutathione; Superoxide dismutase; Lipoprotein **268**, 21

**Transferability**; Commutability; Quality assurance **268**, 73